Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab Sequential Therapy in Elderly Community Patients With Severe Osteoporosis
ChiCTR2500109364Phase 4Recruiting
- Sponsor
- Hefei Second People's Hospital
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of denosumab in osteoporosis (3 arms), sponsored by Hefei Second People's Hospital. Primary endpoint: Bone mineral density (BMD) at 12 months. Started Sep 2025; status: recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ChiCTR2500109364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109364.